PSI-697

851546-61-7

C21H18ClNO3

DMSO : >= 45.8 mg/mL (124.51 mM)

Others

PSI-697 is an oral P-selectin inhibitor with an IC₅₀ of 125 uM^[1]. IC50 & Target: IC50: 125 uM (P-selectin)^[1] In Vitro: PSI-697 inhibits the binding of a soluble human P-selectin to PSGL-1, in a reproducible concentration-dependent manner inhibiting 50% of binding at a concentration of 125 uM in vitro^[1].
In Vivo: PSI-697 (0-50 mg/kg; p.o.) significantly reduces the number of rolling leukocytes by 39% versus vehicle control^[1].
PSI-697 (100 mg/kg; p.o.) reduces thrombus weight by 18% relative to vehicle, without prolonging bleeding time in a rat venous thrombosis model^[1].
PSI-697 (30 mg/kg; p.o.; daily; 6 days) promotes thrombus resolution and decreases inflammation in a baboon model of venous thrombosis^[2].
PSI-697 ((30 mg/kg; i.g.; daily) decreases vein wall injury in a rat stenosis model of venous thrombosis^[2].